---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-009837"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:24:43.379997+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics reports Q4 revenue $4.0M, FY revenue $16.0M; appliance sales up 21% in Q4

## Summary
- Q4 2022 revenue $4.0M vs $4.4M YoY; full-year revenue $16.0M vs $16.9M; $2.5M revenue deferred under ASC 606.
- Q4 appliance arches sold 2,938 (+21% YoY); full-year 12,281 (+8% YoY).
- Gross margin 60% in Q4 (vs 71% YoY) and 63% for FY (vs 75% YoY) due to higher costs and new incentives.
- Cash $3.5M at Dec 31, 2022; raised ~$7.4M net in Jan 2023 private placement.
- Received FDA 510(k) clearance for DNA appliance for mild-to-moderate OSA; acquired patents from Advanced Facialdontics for TMD/Bruxism.

## SEC filing metadata
- accession: 0001493152-23-009837
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315223009837/0001493152-23-009837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315223009837/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-009837
- JSON: https://secwatch.observer/filing/0001493152-23-009837.json
- Plain text: https://secwatch.observer/filing/0001493152-23-009837.txt

## Key facts
- Earnings Releases
  Vivos Therapeutics, Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $4.0 million for the fourth quarter of 2022 and $16.0 million for the full year ended December 31, 2022.
  - Period: fourth quarter and fiscal year ended December 31, 2022
  - Revenue: $4.0 million for the fourth quarter of 2022 and $16.0 million for the full year ended December 31, 2022
  - Result: reported results
  source text: On March 30, 2023, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315223009837/0001493152-23-009837-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.